Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Financial Information of Reportable Segment

Financial information of the Company’s reportable segment for 2024 and 2023 are as follows (in thousands):

	2024			2023
Research and development ("R&D") programs:
CLN-978	$	14,833		$	4,989
CLN-619		25,096			18,667
Zipalertinib		31,875			31,230
CLN-049		7,508			6,170
CLN-617		4,403			5,016
CLN-418		6,471			13,539
Early-stage programs		5,938			5,172
Total R&D program expense		96,124			84,783
Equity-based compensation		37,824			30,438
R&D personnel and operations		31,532			24,930
G&A personnel		14,578			12,835
License agreement obligations		100			26,275
Other segment expenses(1)		16,761			11,828
Loss from operations		(196,919	)		(191,089	)
Other income (expense):
Interest income		29,660			21,627
Other income (expense), net		(199	)		239
Net loss before income taxes		(167,458	)		(169,223	)
Income tax expense (benefit)		117			(14,122	)
Net loss		(167,575	)		(155,101	)
Net loss attributable to noncontrolling interests		(192	)		(1,939	)
Net loss attributable to Cullinan	$	(167,383	)	$	(153,162	)

(1)Other segment expenses for 2024 and 2023 include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; marketing expenses; impairment of long-lived assets; depreciation; and other operating costs.